secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001193125-24-058584
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics Q4/FY2023: VOWST net sales $10.4M Q4, $19.6M YTD; net loss narrows to $113.7M
--------------------------------------------------------------------------------

- Net loss of $113.7M for FY2023 versus $250.2M prior year; Q4 net loss $41.2M vs $68.8M.
- VOWST net sales $10.4M in Q4, $19.6M since June launch; 2,833 enrollment forms, 2,015 new patient starts.
- Restructuring expected to save $75-85M annually; cash and equivalents $128.0M at year-end.
- SER-155 Phase 1b Cohort 2 data readout anticipated in Q3 2024; Fast Track designation awarded.
- Appointed Marella Thorell as EVP/CFO following retirement of David Arkowitz.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/0001193125-24-058584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/d806486d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-058584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer